UPCC 45424 A Multicentre, Open-label, Randomised, Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator's Choice of Treatment in Adults ( 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Enrolling By Invitation
99 years or below
All
Phase
N/A
1 Location
Brief description of study
This research study is designed to learn more about the safety and effectiveness of Acalabrutinib given to individuals who have been diagnosed with Chronic Lymphocytic Leukemia (CLL) and cardiac impairment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Updated on
16 Dec 2024.
Study ID: 856933
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
